Testing an EGFR inhibitor for skin conditions called keratinopathies
Treatments studied
Part of Genetic & congenital, Skin clinical trials.
This trial tests an oral drug called erlotinib (an EGFR inhibitor) in adults with certain genetic skin disorders. It aims to reduce symptoms of thickened, blistering or scaly skin. You may be able to join if you have a confirmed genetic form of these conditions and your skin is moderately affected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a diagnosed keratinopathy like epidermolytic ichthyosis, palmoplantar keratoderma, or pachyonychia congenita confirmed by genetic testing.
- Your skin symptoms must be at least moderate in the doctor's assessment.
- You must stop using certain medications (like oral retinoids or steroids) for at least 4 weeks before starting, and avoid topical treatments for 1 week before the observation period.
- You need to be in generally good health, willing to have blood draws and skin biopsies, and follow study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “skin and blood biomarkers,” meaning measurable signs in the body, in people with ichthyosis to better understand the condition. It may help researchers find ways to track disease activity and evaluate future treatments.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This trial tests how a new drug works in people with actinic keratosis (rough, scaly patches caused by sun damage) on their upper arms or face. You will receive the treatment and have blood samples taken to see how your body processes the medication.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
This early-stage study tests how two experimental medicines (povorcitinib by mouth and ruxolitinib cream on skin) work in healthy volunteers. Researchers will measure how these drugs move through your body and affect your skin to learn if they're safe and effective.
Hear when a new Pachyonychia Congenita trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.